SCHEMBL25373947

SCHEMBL25373947

CCOC(=O)C(=O)N(Cc1ccccc1)Cc1ccc(C)cc1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 1/20 0.46
▸ ALDH1A1 P00352 6/20 0.43
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ MAPT P10636 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ ERBB2 P04626 1/20 0.40
▸ PSMB8 P28062 1/20 0.40
▸ PSMB5 P28074 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25376544 0.94 TRPM8 (0.42) TRPM8ALDH1A1TSHRMAPK1MEN1
SCHEMBL25373573 0.94 TRPM8 (0.42) TRPM8ALDH1A1TSHRMAPK1MEN1
SCHEMBL25376252 0.83 MEN1 (0.44) TRPM8ALDH1A1TSHRMAPK1MEN1
SCHEMBL25375165 0.81 TSHR (0.46) TRPM8ALDH1A1TSHRMAPK1KMT2A
SCHEMBL25376054 0.79 TRPM8 (0.45) TRPM8ALDH1A1TSHRMAPK1MEN1
SCHEMBL25374119 0.78 TSPO (0.51) TRPM8ALDH1A1MEN1KMT2AMAPT
SCHEMBL1855682 0.78 ALDH1A1 (0.48) TRPM8ALDH1A1TSHRMAPK1MEN1
SCHEMBL1853180 0.78 LPAR1 (0.53) ALDH1A1SMN1; SMN2
SCHEMBL25377644 0.78 HDAC1 (0.50) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL25376017 0.77 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 TRPM8 4439/4885ALDH1A1 29/4885TSHR 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback